TSX runs higher on rate cut expectations
WARREN, N.J. - Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced Tuesday it is expanding its collaboration with Microsoft (NASDAQ:MSFT) and Databricks to develop a beta version of its PredicTcell model with a focus on oncology. Microsoft, currently valued at $3.94 trillion and showing robust revenue growth of ~15% over the last twelve months, continues to strengthen its position in healthcare technology. According to InvestingPro analysis, while the tech giant appears overvalued at current levels, it maintains a GREAT financial health score.
The company’s artificial intelligence initiative, Tevogen.AI, has begun curating an oncology dataset that will be combined with its initial virology dataset to enhance the accuracy of the model. The development follows Tevogen.AI’s recently published international patent application for machine learning systems that predict immunologically active peptides, which are crucial for developing targeted therapies for cancers and infectious diseases.
"We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model," said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, in a press release statement.
The expanded collaboration aims to develop enhanced analytics and visualization tools for the PredicTcell model to support Tevogen’s internal research and development teams. The company also plans to explore external market opportunities as a potential revenue source.
The beta version will incorporate oncology targets, which according to the company, could potentially accelerate cancer immunotherapy development. The project will be powered by the Databricks Data Intelligence Platform with support from their engineering teams.
Tevogen Bio is a publicly traded biopharmaceutical company focused on developing therapies for cancers and infectious diseases. For detailed analysis of Microsoft and other major tech companies, InvestingPro subscribers have access to over 20 exclusive ProTips and comprehensive financial metrics that help make informed investment decisions.
In other recent news, Microsoft reported a strong performance in its fourth-quarter earnings, surpassing expectations in both revenue and earnings. The company experienced a notable acceleration in its Azure cloud computing business, with Azure growth reaching 39% in constant currency. This growth rate exceeded analyst projections by more than 400 basis points, as highlighted by DA Davidson. UBS also noted this impressive Azure performance, describing it as a "material 4-point Azure growth rate beat" for the second consecutive quarter.
In light of these results, several research firms, including Stifel, UBS, and DA Davidson, raised their price targets for Microsoft to $650 while maintaining a Buy rating. Stifel specifically pointed to strong momentum in Microsoft’s Fabric data platform, supported by positive partner checks and commentary during the earnings report. Additionally, Microsoft announced plans to significantly increase its capital expenditure, intending to spend over $30 billion in the current quarter, marking at least a 50% increase compared to the same period last year. This decision aligns with the company’s ongoing efforts to enhance its AI infrastructure, alongside other tech giants like Meta Platforms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.